Clinical Dilemmas in Viral Liver Disease

Copyright © 2010 Blackwell Publishing Ltd

Clinical Dilemmas in Viral Liver Disease

Editor(s): Graham R. Foster, K. Rajender Reddy

Published Online: 10 MAR 2010

Print ISBN: 9781405179058

Online ISBN: 9781444319590

DOI: 10.1002/9781444319590

About this Book

Product Information

About The Product

Clinical Dilemmas in Viral Liver Disease is a practical up-to-date handbook providing answers to the questions and challenges that arise in day-to-day practice.

Each short chapter addresses a different topic and provides evidence-based guidance on subjects ranging from optimizing current management through to special management problems and novel treatments.

This book is suitable for all medical professionals involved in the care of patients with viral liver disease: established and trainee hepatologists, pediatric hepatologists, pathologists, radiologists, transplant surgeons and nurse specialists

Table of contents

    1. You have free access to this content
      Front Matter (pages I–XI)

  2. Part I: Investigating the Liver

    1. Chapter 1

      Non-Invasive Markers of Liver Fibrosis: Useful or Useless? (pages 1–5)

      Pierre Bedossa

    2. Chapter 2

      Liver Biopsy in Hepatitis C Patients with Easy-to-Treat Characteristics: Should We Bother or Just Do Biomarkers? (pages 6–8)

      Michelle Lai and Nezam Afdhal

    3. Chapter 3

      Screening for Hepatocellular Carcinoma in Viral Liver Disease: Is Ultrasound Enough? (pages 9–12)

      Amit G. Singal and Jorge A. Marrero

    4. Chapter 4

      Genomic Investigations in Viral Hepatitis: Likely to Help or Hinder? (pages 13–18)

      Guohong Deng, Yasser El sherif and Mark R. Thursz

    5. Chapter 5

      Affective and Cognitive Disorders in Hepatitis C Infection: Are They Real and What are the Mechanisms? (pages 19–23)

      Markus Gess, Daniel M. Forton, Howard C. Thomas and Simon D. Taylor-Robinson

  3. Part II: Today's Therapies - Section 1: HCV

    1. Chapter 6

      Acute Hepatitis: Treat Immediately or Give a Chance to Spontaneously Clear? (pages 25–33)

      Ranjeeta Bahirwani and David E. Kaplan

    2. Chapter 7

      Management of HCV Genotype 1 Non-Responders/Relapsers: A European Perspective (pages 34–37)

      Harald Farnik and Stefan Zeuzem

    3. Chapter 8

      HCV Genotype 1: How are you Managing the Non-Responders and Relapsers? A North American Perspective (pages 38–42)

      Michael W. Fried

    4. Chapter 9

      Management of HCV-2 and HCV-3 Non-Responders and Relapsers (pages 43–46)

      Giada Sebastiani and Alfredo Alberti

    5. Chapter 10

      Management of HCV Infection in Patients with Thalassemia and Sickle Cell Disease (pages 47–49)

      Paul Telfer and Banu Kaya

    6. Chapter 11

      Management of HCV in Dialysis Patients (pages 50–54)

      Fabrizio Fabrizi and Paul Martin

    7. Chapter 12

      Management of HCV in Patients with a Renal Transplant (pages 55–57)

      Richard Marley and Janet Dearden

    8. Chapter 13

      Management of HCV in Patients with Psychiatric Comorbidity (pages 58–60)

      Alexander Evans and William Rosenberg

    9. Chapter 14

      Morbid Obesity and HCV: Management Strategies (pages 61–64)

      Venessa Pattullo and Jenny Heathcote

    10. Chapter 15

      Management of Cytopenias during Chronic Hepatitis C Therapy (pages 65–69)

      Alyson N. Fox and Vinod K. Rustgi

    11. Chapter 16

      Management of Patients with Multiple HCV Genotypes (pages 70–72)

      Peter Ferenci

    12. Chapter 17

      HCV and Injecting Drug Users: How do we Approach Them? (pages 73–75)

      Olav Dalgard

    13. Chapter 18

      HCV with and without Autoimmune Features: How do you Sort them out and Manage? (pages 76–81)

      M. Shadab Siddiqui and Steven L. Flamm

    14. Chapter 19

      HCV and Iron Excess: The Interaction and how to Handle it (pages 82–87)

      Bryan D. Maliken and Kris V. Kowdley

    15. Chapter 20

      Management of Patients with Genotype 3 Chronic Hepatitis C: Can we Change the Duration of Therapy? (pages 88–93)

      Alessandra Mangia, Valeria Piazzolla and Angelo Andriulli

    16. Chapter 21

      Management of Hepatitis C in Children (pages 94–98)

      Maureen M. Jonas

    17. Chapter 22

      Controlling Symptoms in Chronic HCV on and off Treatment: Does Anything Work? (pages 99–104)

      Brenda A. Appolo

    18. Chapter 23

      Complementary Therapies in Chronic HCV: Exploitation or Something to Offer? (pages 105–109)

      Kelly C. Vranas and K. Rajender Reddy

    19. Chapter 24

      HCV in Liver Transplant Recipients: How do you Approach Them? (pages 110–114)

      Brett E. Fortune and Lisa M. Forman

    20. Chapter 25

      HCV in Patients with Advanced Disease: Do you Treat them and do you have any Caveats? (pages 115–122)

      Gregory T. Everson

  4. Part II: Today's Therapies - Section 2: HBV

    1. Chapter 26

      Management of Acute HBV (pages 123–128)

      Dennis A. Freshwater and David J. Mutimer

    2. Chapter 27

      Rethinking the Inactive Carrier State: Management of Patients with Low-Replicative HBeAg-Negative Chronic Hepatitis B and Normal Liver Enzymes (pages 129–134)

      Ilan S. Weisberg and Ira M. Jacobson

    3. Chapter 28

      HBeAg-Negative Chronic Hepatitis B Infection with Abnormal Transaminases and Minimal Changes on Liver Biopsy (pages 135–137)

      Graham R. Foster

    4. Chapter 29

      Combination Therapy for Chronic Hepatitis B Virus Infection: Should we use it ab initio or Sequentially? (pages 138–141)

      William Alazawi and Graham R. Foster

    5. Chapter 30

      Management of Hepatitis B Virus Infection in Pregnancy (pages 142–145)

      Eleri S. W. Wilson-Davies and William F. Carman

    6. Chapter 31

      Management of Hepatitis B in Children (pages 146–150)

      Maureen M. Jonas

    7. Chapter 32

      Hepatitis B Infection in Surgeons and Healthcare Workers: What should we do to Protect Patients? (pages 151–153)

      Graham R. Foster

    8. Chapter 33

      HBV in the Poorly Compliant Patient: Dare we Start Oral Drugs? (pages 154–158)

      Tin Nguyen, Paul Desmond and Stephen Locarnini

    9. Chapter 34

      Acute Liver Failure and HBV: Is there a Role for HBV Therapy? (pages 159–162)

      Hank S. Wang and Tram T. Tran

    10. Chapter 35

      High-Risk Needle Exposure in Hepatitis B Vaccine Failures: What are the Options? (pages 163–167)

      Pari Shah and Kimberly A. Forde

    11. Chapter 36

      Antiviral Prophylactic Treatment of Chronic Hepatitis B to Prevent Viral Reactivation during Cytotoxic Chemotherapy (pages 168–173)

      Mohsin Ali and K. Rajender Reddy

    12. Chapter 37

      Management of Hepatitis B in HIV-Infected and other Immunosuppressed Patients (pages 174–180)

      Kaiser Raja and Douglas T. Dieterich

    13. Chapter 38

      Lamivudine and Adefovir Resistance: What should we do? (pages 181–187)

      Geoff M. Dusheiko

    14. Chapter 39

      HBV Therapy Following Unsuccessful Interferon Therapy: How do you see the Role for Oral Therapies? (pages 188–191)

      Grace M. Chee and Fred F. Poordad

    15. Chapter 40

      Hepatitis B and Hepatitis C Co-Infection (pages 192–195)

      Quentin M. Anstee, Belinda C. Smith and Howard C. Thomas

  5. Part III: Clinical Set-up

    1. Chapter 41

      The Nurse Practitioner and the Physician Assistant: Their Role in HCV Management (pages 197–201)

      Brenda A. Appolo

    2. Chapter 42

      Non-Specialist Management in General Practice of Chronic Hepatitis C Liver Disease: Cost-Effective or Foolish Cost Cutting? (pages 202–205)

      Chris Helen Ford

  6. Part IV: The Future

    1. Chapter 43

      The Future of HCV Therapy: With or without Interferon and Ribavirin? (pages 207–213)

      Mark Sulkowski

    2. Chapter 44

      Protease and Polymerase Inhibitors for HCV (pages 214–220)

      Christoph Sarrazin

    3. Chapter 45

      HCV Vaccines: Coming Soon? (pages 221–225)

      David E. Kaplan

    4. Chapter 46

      New Drugs for Hepatitis B: What is in the Pipeline? (pages 226–229)

      Cihan Yurdaydýn, A. Mithat Bozdayý, Ramazan Idilman and Hakan Bozkaya

    5. Chapter 47

      Hepatitis B – a Therapeutic Vaccine: Hope or Hype? (pages 230–235)

      Rosa Di Stefano and Antonio Craxì

    6. Chapter 48

      Novel Interferons: Is there Life in the Old Dog Yet? (pages 236–238)

      Graham R. Foster

  7. Part V: Ongoing Controversies

    1. Chapter 49

      Is Interferon a Valuable First-Line Therapy for HBeAg-Positive HBV? (pages 239–245)

      Patrick Marcellin, Rami Moucari, Olivier Lada and Tarik Asselah

    2. Chapter 50

      Most Patients with Hepatitis C will Die from their Disease (pages 246–248)

      Graham R. Foster and Steven Masson

    3. Chapter 51

      Most Patients with Hepatitis C will Die with their Disease (pages 249–251)

      Ronald L. Koretz

    1. You have free access to this content
      Index (pages 252–260)

SEARCH